Paclitaxel

製品コードS1150 バッチS115012

印刷

化学情報

Chemical Structure Synonyms NSC 125973，PTX Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C47H51NO14
分子量 853.91 CAS No. 33069-62-4
Solubility (25°C)* 体外 DMSO 100 mg/mL (117.1 mM)
Ethanol 23 mg/mL (26.93 mM)
Water Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 パクリタキセル (Paclitaxel (NSC 125973, PTX)) は微小管を安定化することで脱重合を阻害します。ヒト血管内皮細胞における IC50 は 0.1 pM です。
in vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of this compound inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to this chemical at ultra low concentrations. Inhibition of human ECs by this compound at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, this chemical at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of this compound on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of this chemical with or without SMF on K562 cells is correlated with DNA damage. [2] This compound alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
in vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg this compound significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ

Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.
動物実験 動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
投薬量 20 mg/kg
投与方法 Administered via i.v.

参考

  • https://pubmed.ncbi.nlm.nih.gov/12544254/
  • https://pubmed.ncbi.nlm.nih.gov/22447825/
  • https://pubmed.ncbi.nlm.nih.gov/22433711/
  • https://pubmed.ncbi.nlm.nih.gov/22374518/
  • https://pubmed.ncbi.nlm.nih.gov/15015572/

カスタマーフィードバック

Data from [RSC Adv, 2011, 1, 884-892]

Data from [Data independently produced by , , Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916]

Data from [Data independently produced by , , Clin Cancer Res, 2017, 23(15):4364-4375]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Activation of lysosomal iron triggers ferroptosis in cancer [ Nature, 2025, 10.1038/s41586-025-08974-4] PubMed: 40335696
CD36-mediated endocytosis of proteolysis-targeting chimeras [ Cell, 2025, S0092-8674(25)00386-1] PubMed: 40250420
Signal-induced NLRP3 phase separation initiates inflammasome activation [ Cell Res, 2025, 35(6):437-452.] PubMed: 40164768
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy [ Cell Stem Cell, 2025, S1934-5909(25)00265-6] PubMed: 40812300
Immune-modulative nano-gel-nano system for patient-favorable cancer therapy [ Bioact Mater, 2025, 43:67-81] PubMed: 39328776
A novel pathway for stemness propagation and chemoresistance in non-small cell lung cancer via phosphorylated PKM2-loaded small extracellular vesicles [ Theranostics, 2025, 15(8):3439-3461] PubMed: 40093893
KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules [ Dev Cell, 2025, S1534-5807(25)00151-0] PubMed: 40157365
Apoptotic breast cancer cells after chemotherapy induce pro-tumour extracellular vesicles via LAP-competent macrophages [ Redox Biol, 2025, 80:103485] PubMed: 39756316
Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors [ Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2360] PubMed: 39945650
ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2 [ Biomark Res, 2025, 13(1):17] PubMed: 39849645

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。